{
    "table_id": "finqa_1933af4ca5",
    "source": "finqa",
    "original_metadata": {
        "source_dataset": "finqa",
        "document_id": "VRTX/2005/page_103.pdf-1",
        "pre_text_caption_evidence": [
            "value , which may be maturity , the company does not consider these investments to be other-than-temporarily impaired as of december 31 , 2005 and 2004 .",
            "gross realized gains and losses for 2005 were $ 15000 and $ 75000 , respectively .",
            "gross realized gains and losses for 2004 were $ 628000 and $ 205000 , respectively .",
            "gross realized gains for 2003 were $ 1249000 .",
            "there were no gross realized losses for 2003 .",
            "maturities stated are effective maturities .",
            "f .",
            "restricted cash at december 31 , 2005 and 2004 , the company held $ 41482000 and $ 49847000 , respectively , in restricted cash .",
            "at december 31 , 2005 and 2004 the balance was held in deposit with certain banks predominantly to collateralize conditional stand-by letters of credit in the names of the company's landlords pursuant to certain operating lease agreements .",
            "g .",
            "property and equipment property and equipment consist of the following at december 31 ( in thousands ) : depreciation expense for the years ended december 31 , 2005 , 2004 and 2003 was $ 26307000 , $ 28353000 and $ 27988000 respectively .",
            "in 2005 and 2004 , the company wrote off certain assets that were fully depreciated and no longer utilized .",
            "there was no effect on the company's net property and equipment .",
            "additionally , the company wrote off or sold certain assets that were not fully depreciated .",
            "the net loss on disposal of those assets was $ 344000 for 2005 and $ 43000 for 2004 .",
            "h .",
            "investments in accordance with the company's policy , as outlined in note b , \"accounting policies\" the company assessed its investment in altus pharmaceuticals , inc .",
            "( \"altus\" ) , which it accounts for using the cost method , and determined that there had not been any adjustments to the fair values of that investment which would indicate a decrease in its fair value below the carrying value that would require the company to write down the investment basis of the asset , as of december 31 , 2005 and december 31 , 2004 .",
            "the company's cost basis carrying value in its outstanding equity and warrants of altus was $ 18863000 at december 31 , 2005 and 2004. ."
        ],
        "question": "what is the percent change in net loss on disposal of assets between 2004 and 2005?"
    },
    "dimensions": {
        "rows": 7,
        "columns": 3
    },
    "schema": {
        "columns": [
            "",
            "2005",
            "2004"
        ],
        "dtypes": {
            "": "object",
            "2005": "object",
            "2004": "object"
        }
    }
}